PremiumCompany AnnouncementsCorcept Therapeutics Reports Q1 2025 Financial Results Closing Bell Movers: Palantir falls 9%, Ford down 2% on earnings Corcept Therapeutics Reports Q1 2025 Financial Results PremiumThe FlyCorcept Therapeutics initiates trial of Phase 2 trial BELLA Corcept Therapeutics price target raised to $131 from $128 at Piper Sandler Biotech Alert: Searches spiking for these stocks today PremiumThe FlyCorcept Therapeutics price target raised to $128 from $78 at Piper Sandler Corcept Therapeutics price target raised to $150 from $76 at Truist Corcept Therapeutics: Promising Future with Positive Trial Results and Strong Market Position